Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gazyva

- PMLiVE

Tecentriq gains first IO approval in triple negative breast cancer

A coup for Roche in IO field dominated by Keytruda

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

Roche - Basel

Roche files Venclexta plus Gazyva in CLL

Chemo-free combo assessed via FDA's Real-Time review

- PMLiVE

Roche buys gene therapy specialist Spark for $4.3bn

Can compete with rival Novartis in fast-developing area

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

NICE decision puts NHS in vanguard for new use

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

- PMLiVE

Ocrevus helps Roche shrug off biosimilars in 2018

Good news after Alzheimer's failure

- PMLiVE

Another amyloid bust as Roche pulls crenezumab trials

Undermines amyloid hypothesis hopes. including Biogen candidate

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

Hardy returns to Genentech as CEO

In other news, Vertex fires chief operating officer

- PMLiVE

Chugai gains FDA breakthrough status for rare CNS treatment

Adds to company's BTD roll-call

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links